S1P Receptor

S1P Receptor製品

• All (25)
• S1P Receptor阻害剤 (5)
• S1P Receptor活性剤(3)
• S1P Receptor拮抗剤(4)
• S1P Receptor作動薬(5)
• S1P Receptorモジュレータ(3)
• 新製品

製品コード	製品名称	製品説明	文献中Selleckの製品使用例	お客様のフィードバック
S5002	Fingolimod (FTY720) HCl	Fingolimod (FTY720, Fingolimod Hydrochloride) HCl is a S1P antagonist with IC50 of 0.033 nM in K562, and NK cells.Please use saline solution rather than PBS for dilutions. PBS may cause precipitation.	J Exp Med, 2024, 221(4)e20232104 Cell Death Dis, 2024, 15(9):678 Antibiotics (Basel), 2024, 13(7)621
S7791	PMA (Phorbol 12-myristate 13-acetate)	PMA (Phorbol 12-myristate 13-acetate), a potent activator of PKC, is active at nanomolar concentrations. Phorbol 12-myristate 13-acetate (PMA) induces sphingosine-1-phosphate (S1P).	Cell Rep Med, 2024, 5(8):101686 J Exp Clin Cancer Res, 2024, 43(1):105 Cell Mol Biol Lett, 2024, 29(1):77
S5950	Fingolimod (FTY-720)	Fingolimod (FTY-720) is a sphingosine 1-phosphate receptor modulator used for the treatment of relapsing-remitting multiple sclerosis.	Nat Commun, 2024, 15(1):6970 Oncol Res, 2023, 31(6):867-875 J Clin Invest, 2022, 132(3)e153604
S7179	Siponimod (BAF312)	BAF312 (Siponimod) is a next-generation S1P receptor modulator, selective for S1P1 and S1P5 receptors with EC50 of 0.39 nM and 0.98 nM, exhibits >1000-fold selectivity over S1P2, S1P3 and S1P4 receptors. Phase 3.	Cancers (Basel), 2024, 16(3)574 J Neuroinflammation, 2023, 20(1):35 Cell Res, 2022, 10.1038/s41422-022-00614-0
S7182	JTE 013	JTE 013 is a potent and selective S1P2 antagonist with IC50 of 17.6 nM.	Cell Res, 2022, 10.1038/s41422-022-00614-0 Autophagy, 2022, 1-20 Vascul Pharmacol, 2021, S1537-1891(21)00113-0
S7952	Ozanimod	Ozanimod is a selective oral S1P Receptor 1 modulator. Phase 3.	Front Immunol, 2024, 15:1230735 FASEB J, 2022, 36(2):e22132 China Biotechnology, 2020, (6): 10-19
S8241	Ponesimod	Ponesimod (ACT-128800) is an orally active, selective sphingosine-1-phosphate receptor 1 (S1P1) immunomodulator with EC50 of 5.7 nM.	Cancers (Basel), 2024, 16(3)574 EBioMedicine, 2023, 94:104713 Int J Mol Sci, 2022, 23(18)10311
S6418	PF 429242	PF 429242 is known as a S1P inhibitor with an IC50 of 170 nM, showing no significant inhibition of trypsin, elastase, proteinase K, plasmin, kallikren, factor XIa, thrombin, or furin at concentrations up to 100 μM and only modest inhibition of urokinase (IC50 = 50 μM) and factor Xa (IC50 = 100 μM).	Cell Rep, 2023, 42(6):112586 Nat Commun, 2019, 11;10(1):4621
S0817	SKI-V	SKI V is a noncompetitive and potent inhibitor of non-lipid sphingosine kinase with IC50 of 2 μM for GST-hSK. SKI-V also inhibits PI3K with IC50 of 6 μM for hPI3k. SKI-V decreases formation of the mitogenic second messenger sphingosine-1-phosphate (S1P) and induces apoptosis with antitumor activity.	Cell Death Discov, 2022, 8(1):48 Cell Death Discov, 2022, 8(1):48
E2363New	Etrasimod(APD334)	Etrasimod(APD334) is a potent, selective and orally available antagonist of the sphingosine-1-phosphate-1 (S1P1) receptor with an EC50 value of 1.88 nM in CHO cells.
E0482	MP-A08	MP-A08 is a highly selective ATP competitive sphingosine kinase (SK) inhibitor that targets both SK1 and SK2.
E1917New	SLF1081851 hydrochloride	SLF1081851 hydrochloride is a potential inhibitor of Spns2 that blocks S1P release with an IC50 of 1.93 μM. It can be developed as a probe for studying Spns2 biology and immune modulation.
E1218	K6PC-5	K6PC-5, a ceramide derivative, is a sphingosine kinase 1 (SPHK1) activator and elicits a rapid transient increase in intracellular calcium levels.	Cell Prolif, 2024, e13604. Int J Biol Sci, 2022, 18(7):2994-3005
E1123	K145	K145 is a selective, substrate-competitive and orally active sphingosine kinase-2 (SphK2) inhibitor with an IC50 of 4.3 µM and a Ki of 6.4 µM in biochemical assays.
E1158	CAY10444	CAY10444 (BML-241) is a sphingosine-1-phosphate 3 (S1P3) antagonist, which can inhibit S1P response of S1P3 cell line with 78% inhibition rate and IC50 of 4.6 μM.
S6552	CYM5541	CYM5541 (ML249) is a selective, allosteric agonist of S1P3 with an EC50 of between 72 and 132 nM and exhibits exquisite selectivity over other S1P receptor subtypes in vitro: S1P1 EC50 > 10 μM, S1P2 EC50 > 50 μM, S1P4 EC50 > 50 μM, and S1P5 EC50 > 25 μM.
S4462	CYM-5520	CYM-5520 is a highly selective sphingosine-1-phosphate receptor 2 (S1PR2) agonist with an EC50 of 0.48 µM and does not activate other S1P receptors.
S3412	CYM50308	CYM50308 (ML248) is a potent and selective S1P4 receptor agonist with an EC50 of 56 nM.
E4956New	Ozanimod hydrochloride	Ozanimod hydrochloride(Zeposia, RPC-1063 HCL) is a potent sphingosine 1-phosphate (S1P)receptor modulator and a selective agonist of S1P receptor subtypes 1 (S1P1) and 5 (S1P5) with EC50's of 1.03 nM and 8.6 nM, respectively. It can be used in the trearment of relapsing multiple sclerosis (MS).
E2411	Taurodeoxycholic acid sodium hydrate	Taurodeoxycholic acid sodium hydrate (Sodium taurodeoxycholate monohydrate), a bile acid, is an amphiphilic surfactant molecule synthesized from cholesterol in the liver. It activates S1PR2 pathway in addition to the TGR5 pathway.
S7179	Siponimod (BAF312)	BAF312 (Siponimod) is a next-generation S1P receptor modulator, selective for S1P1 and S1P5 receptors with EC50 of 0.39 nM and 0.98 nM, exhibits >1000-fold selectivity over S1P2, S1P3 and S1P4 receptors. Phase 3.	Cancers (Basel), 2024, 16(3)574 J Neuroinflammation, 2023, 20(1):35 Cell Res, 2022, 10.1038/s41422-022-00614-0
S6552	CYM5541	CYM5541 (ML249) is a selective, allosteric agonist of S1P3 with an EC50 of between 72 and 132 nM and exhibits exquisite selectivity over other S1P receptor subtypes in vitro: S1P1 EC50 > 10 μM, S1P2 EC50 > 50 μM, S1P4 EC50 > 50 μM, and S1P5 EC50 > 25 μM.
S4462	CYM-5520	CYM-5520 is a highly selective sphingosine-1-phosphate receptor 2 (S1PR2) agonist with an EC50 of 0.48 µM and does not activate other S1P receptors.
S3412	CYM50308	CYM50308 (ML248) is a potent and selective S1P4 receptor agonist with an EC50 of 56 nM.
E4956New	Ozanimod hydrochloride	Ozanimod hydrochloride(Zeposia, RPC-1063 HCL) is a potent sphingosine 1-phosphate (S1P)receptor modulator and a selective agonist of S1P receptor subtypes 1 (S1P1) and 5 (S1P5) with EC50's of 1.03 nM and 8.6 nM, respectively. It can be used in the trearment of relapsing multiple sclerosis (MS).
S6418	PF 429242	PF 429242 is known as a S1P inhibitor with an IC50 of 170 nM, showing no significant inhibition of trypsin, elastase, proteinase K, plasmin, kallikren, factor XIa, thrombin, or furin at concentrations up to 100 μM and only modest inhibition of urokinase (IC50 = 50 μM) and factor Xa (IC50 = 100 μM).	Cell Rep, 2023, 42(6):112586 Nat Commun, 2019, 11;10(1):4621
S0817	SKI-V	SKI V is a noncompetitive and potent inhibitor of non-lipid sphingosine kinase with IC50 of 2 μM for GST-hSK. SKI-V also inhibits PI3K with IC50 of 6 μM for hPI3k. SKI-V decreases formation of the mitogenic second messenger sphingosine-1-phosphate (S1P) and induces apoptosis with antitumor activity.	Cell Death Discov, 2022, 8(1):48 Cell Death Discov, 2022, 8(1):48
E0482	MP-A08	MP-A08 is a highly selective ATP competitive sphingosine kinase (SK) inhibitor that targets both SK1 and SK2.
E1917New	SLF1081851 hydrochloride	SLF1081851 hydrochloride is a potential inhibitor of Spns2 that blocks S1P release with an IC50 of 1.93 μM. It can be developed as a probe for studying Spns2 biology and immune modulation.
E1123	K145	K145 is a selective, substrate-competitive and orally active sphingosine kinase-2 (SphK2) inhibitor with an IC50 of 4.3 µM and a Ki of 6.4 µM in biochemical assays.
S7791	PMA (Phorbol 12-myristate 13-acetate)	PMA (Phorbol 12-myristate 13-acetate), a potent activator of PKC, is active at nanomolar concentrations. Phorbol 12-myristate 13-acetate (PMA) induces sphingosine-1-phosphate (S1P).	Cell Rep Med, 2024, 5(8):101686 J Exp Clin Cancer Res, 2024, 43(1):105 Cell Mol Biol Lett, 2024, 29(1):77
E1218	K6PC-5	K6PC-5, a ceramide derivative, is a sphingosine kinase 1 (SPHK1) activator and elicits a rapid transient increase in intracellular calcium levels.	Cell Prolif, 2024, e13604. Int J Biol Sci, 2022, 18(7):2994-3005
E2411	Taurodeoxycholic acid sodium hydrate	Taurodeoxycholic acid sodium hydrate (Sodium taurodeoxycholate monohydrate), a bile acid, is an amphiphilic surfactant molecule synthesized from cholesterol in the liver. It activates S1PR2 pathway in addition to the TGR5 pathway.
S5002	Fingolimod (FTY720) HCl	Fingolimod (FTY720, Fingolimod Hydrochloride) HCl is a S1P antagonist with IC50 of 0.033 nM in K562, and NK cells.Please use saline solution rather than PBS for dilutions. PBS may cause precipitation.	J Exp Med, 2024, 221(4)e20232104 Cell Death Dis, 2024, 15(9):678 Antibiotics (Basel), 2024, 13(7)621
S7182	JTE 013	JTE 013 is a potent and selective S1P2 antagonist with IC50 of 17.6 nM.	Cell Res, 2022, 10.1038/s41422-022-00614-0 Autophagy, 2022, 1-20 Vascul Pharmacol, 2021, S1537-1891(21)00113-0
E2363New	Etrasimod(APD334)	Etrasimod(APD334) is a potent, selective and orally available antagonist of the sphingosine-1-phosphate-1 (S1P1) receptor with an EC50 value of 1.88 nM in CHO cells.
E1158	CAY10444	CAY10444 (BML-241) is a sphingosine-1-phosphate 3 (S1P3) antagonist, which can inhibit S1P response of S1P3 cell line with 78% inhibition rate and IC50 of 4.6 μM.
S7179	Siponimod (BAF312)	BAF312 (Siponimod) is a next-generation S1P receptor modulator, selective for S1P1 and S1P5 receptors with EC50 of 0.39 nM and 0.98 nM, exhibits >1000-fold selectivity over S1P2, S1P3 and S1P4 receptors. Phase 3.	Cancers (Basel), 2024, 16(3)574 J Neuroinflammation, 2023, 20(1):35 Cell Res, 2022, 10.1038/s41422-022-00614-0
S6552	CYM5541	CYM5541 (ML249) is a selective, allosteric agonist of S1P3 with an EC50 of between 72 and 132 nM and exhibits exquisite selectivity over other S1P receptor subtypes in vitro: S1P1 EC50 > 10 μM, S1P2 EC50 > 50 μM, S1P4 EC50 > 50 μM, and S1P5 EC50 > 25 μM.
S4462	CYM-5520	CYM-5520 is a highly selective sphingosine-1-phosphate receptor 2 (S1PR2) agonist with an EC50 of 0.48 µM and does not activate other S1P receptors.
S3412	CYM50308	CYM50308 (ML248) is a potent and selective S1P4 receptor agonist with an EC50 of 56 nM.
E4956New	Ozanimod hydrochloride	Ozanimod hydrochloride(Zeposia, RPC-1063 HCL) is a potent sphingosine 1-phosphate (S1P)receptor modulator and a selective agonist of S1P receptor subtypes 1 (S1P1) and 5 (S1P5) with EC50's of 1.03 nM and 8.6 nM, respectively. It can be used in the trearment of relapsing multiple sclerosis (MS).
S5950	Fingolimod (FTY-720)	Fingolimod (FTY-720) is a sphingosine 1-phosphate receptor modulator used for the treatment of relapsing-remitting multiple sclerosis.	Nat Commun, 2024, 15(1):6970 Oncol Res, 2023, 31(6):867-875 J Clin Invest, 2022, 132(3)e153604
S7952	Ozanimod	Ozanimod is a selective oral S1P Receptor 1 modulator. Phase 3.	Front Immunol, 2024, 15:1230735 FASEB J, 2022, 36(2):e22132 China Biotechnology, 2020, (6): 10-19
S8241	Ponesimod	Ponesimod (ACT-128800) is an orally active, selective sphingosine-1-phosphate receptor 1 (S1P1) immunomodulator with EC50 of 5.7 nM.	Cancers (Basel), 2024, 16(3)574 EBioMedicine, 2023, 94:104713 Int J Mol Sci, 2022, 23(18)10311
E2363New	Etrasimod(APD334)	Etrasimod(APD334) is a potent, selective and orally available antagonist of the sphingosine-1-phosphate-1 (S1P1) receptor with an EC50 value of 1.88 nM in CHO cells.
E1917New	SLF1081851 hydrochloride	SLF1081851 hydrochloride is a potential inhibitor of Spns2 that blocks S1P release with an IC50 of 1.93 μM. It can be developed as a probe for studying Spns2 biology and immune modulation.
E4956New	Ozanimod hydrochloride	Ozanimod hydrochloride(Zeposia, RPC-1063 HCL) is a potent sphingosine 1-phosphate (S1P)receptor modulator and a selective agonist of S1P receptor subtypes 1 (S1P1) and 5 (S1P5) with EC50's of 1.03 nM and 8.6 nM, respectively. It can be used in the trearment of relapsing multiple sclerosis (MS).
E4956New	Ozanimod hydrochloride	Ozanimod hydrochloride(Zeposia, RPC-1063 HCL) is a potent sphingosine 1-phosphate (S1P)receptor modulator and a selective agonist of S1P receptor subtypes 1 (S1P1) and 5 (S1P5) with EC50's of 1.03 nM and 8.6 nM, respectively. It can be used in the trearment of relapsing multiple sclerosis (MS).